AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Florida-based Nanobac Pharmaceuticals has signed an agreement with Calgenex granting Nanobac an option to assess fellow US firm Calgenex' drug-delivery technology for potential use with Nanobac's drug combinations used in treating atherosclerosis, prostatitis and other pathologic calcification diseases. The technology includes a novel combination of bisphosphonate and silicic acid.
"Today's option agreement is a testament towards our goal of evaluating the ...